Evidence map›Paper›PMID 40920810›Full record

ArticlePLoS pathogens2025

Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells.

Michael P Schwoerer, Sebastian Carver, Aaron E Lin, Jianche Liu, Thomas R Cafiero, Keith A Berggren, Serene Dhawan, Saori Suzuki, Brigitte Heller, Celeste Rodriguez and 4 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael P SchwoererDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Sebastian CarverDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Aaron E LinDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Jianche LiuDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Thomas R CafieroDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Keith A BerggrenDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Serene DhawanPrinceton Neuroscience Institute, Princeton University, Princeton, New Jersey, United States of America.
Saori SuzukiDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Brigitte HellerDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Celeste RodriguezDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Aoife K O'ConnellNational Emerging Infectious Diseases Laboratories, Boston University, Boston, Massachusetts, United States of America.
Hans P GertjeNational Emerging Infectious Diseases Laboratories, Boston University, Boston, Massachusetts, United States of America.
Nicholas A CrosslandNational Emerging Infectious Diseases Laboratories, Boston University, Boston, Massachusetts, United States of America.
Alexander PlossDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.ORCID 0000-0001-9322-7252

Funding

PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007388 · NIGMS · PRINCETON UNIVERSITY · PI CRISTEA, ILEANA M. · 1985 to 2022
$27.4M
Rational design and efficacy testing of vaccines against HCVR01AI168048 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Alexander Andrianov, Thomas R Fuerst · 2022 to 2026
$7.1M
Genetic Viral and Host Adaptations to Breach Species Barriers of HCVR01AI107301 · NIAID · PRINCETON UNIVERSITY · PI Thomas Pietschmann, Alexander Ploss · 2013 to 2026
$6.0M
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infectionR01AI138797 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PLOSS, ALEXANDER, SU, LISHAN · 2018 to 2022
$3.9M
Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment ResponseR01AI146917 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI DAHARI, HAREL · 2020 to 2024
$3.5M
Targeting hepatitis B virus cccDNA during HBV/HIV co-infectionR01AI181664 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2024 to 2025
$3.0M
Mechanisms of hepatitis B virus cccDNA formationR01AI153236 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2020 to 2024
$2.8M
Vectra Polaris Quantitative Pathology Imaging SystemS10OD030269 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2021 to 2021
$402k
Ventana Discovery Ultra Research Autostainer: an Ex+ Core serviceS10OD026983 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2019 to 2019
$207k
NIAID NIH HHS R01 AI107301NIAID NIH HHS R01 AI138797NIAID NIH HHS R01 AI146917NIAID NIH HHS R01 AI153236NIAID NIH HHS R01 AI168048NIAID NIH HHS R01 AI181664NIGMS NIH HHS T32 GM007388NIH HHS S10 OD026983NIH HHS S10 OD030269
6 · The paper itself

Abstract

Hepatitis C virus (HCV) exhibits a narrow species tropism, causing robust infections only in humans and experimentally inoculated chimpanzees. While many host factors and restriction factors are known, many more likely remain unknown, which has limited the development of mouse or other small animal models for HCV. One putative restriction factor, the black flying fox orthologue of receptor transporter protein 4 (RTP4), was previously shown to potently inhibit viral genome replication of several ER-replicating RNA viruses. Since the murine but not the human ortholog is a potent inhibitor of HCV, we aimed to analyze the potential role for RTP4 in restricting HCV replication in mice. We demonstrated that mouse RTP4 (mmRTP4) functions as a dominant inhibitor of HCV infection. Via interspecies domain-mapping, we identified the zinc-finger domain (ZFD) of murine RTP4 as essential for inhibiting HCV, consistent with prior work. Introducing mmRTP4 into HCV-infected Huh7 cells profoundly reduced HCV NS5A protein production and virion release, demonstrating that mmRTP4 can also disrupt already established HCV replication complexes. This inhibition of HCV was not driven by induction of interferon-stimulated genes based on bulk RNA-seq, suggesting that mmRTP4 might directly act on HCV replication. Indeed, by in situ proximity ligation, we found that mmRTP4 directly associates with the HCV NS5A protein significantly more than human RTP4 during infection. However, disrupting RTP4 expression in mice expressing humanized alleles of CD81 and occludin (OCLN) - the species specific cellular factors mediating HCV uptake - did not increase permissiveness irrespective of the immunocompetence of the mice. Collectively, our work provides detailed insights into the role of RTP4 in contributing to HCV's narrow host range and will inform downstream development of a more comprehensive small-animal model for this important pathogen.

Indexed as

HepacivirusHepatitis CVirus ReplicationAnimalsHumansMiceViral Nonstructural ProteinsViral Nonstructural Proteins

Identifiers

PMID40920810
PMCPMC12431671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.